Ranbaxy launches Pravastatin Sodium 80 mg tablets in USA, to benefit from 180 day exclusivity

Ranbaxy Laboratories Ltd on June 25, 2007, has announced that the Company's wholly owned subsidiary, Ranbaxy Pharmaceuticals Inc. (RPI), has launched Pravastatin Sodium 80 mg Tablets in the U.S. healthcare system.

Being the first-to-file, the Company will enjoy a 180 day exclusivity for Pravastatin 80mg and benefit from the commercial gains during this period. The annual sales for Pravastatin 80mg are $ 209 Mn (IMS: MAT - Dec. 2006).

"We will make Pravastatin Sodium 80 mg Tablets available to all classes of trade immediately, and our Ranbaxy Sales and Distribution Teams will be doing everything to have product in the hands of our customers as quickly as possible. We are delighted to have this product formulation as an addition to our ever expanding product portfolio of affordable generic alternatives," said Jim Meehan, Vice President of Sales and Marketing for RPI, USA.

Pravastatin is indicated in the treatment of primary prevention of coronary events such as in hypercholesterolemic patients without clinically evident coronary heart disease. Pravastatin is also indicated to reduce the risk of myocardial infarction, reduce the risk of undergoing myocardial revascularization procedures and reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. It is also indicated for treatment in the secondary prevention of cardiovascular events such as in patients with clinically evident coronary heart disease to reduce the risk of stroke and stroke / transient ischemic attack (TIA), and slow the progression of coronary atherosclerosis.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, USA, is a wholly owned subsidiary of the Company, India's largest pharmaceutical Company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Source : Equity Bulls

Keywords